On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

NetworkNewsBreaks – INmune Bio, Inc. (NASDAQ: INMB) to Present at the World Immunotherapy Congress in San Diego

Company: INmune Bio, Inc. (INMB)
Category: News

INmune Bio (NASDAQ: INMB) this morning announced that the company’s co-founders, R.J. Tesi, M.D., and Mark Lowdell, Ph.D., are presenting at the World Immunotherapy Congress USA during the Festival of Biologics San Diego, taking place from March 3rd to 5th. Dr. Tesi and Dr. Lowdell serve as the company’s chief executive office and chief scientific officer, respectively. The World Immunotherapy Congress USA connects leaders and innovators of the international immunotherapy industry to discuss the latest in leading-edge ideas and approaches. The event takes place during the Festival of Biologics San Diego, a collection of four biotechnology and healthcare conferences including the World Immunotherapy Congress USA, as well as America’s Antibody Congress, World Biosimilar Congress and Clinical Trials Americas. “The innate immune system is often overlooked in the fight against disease. We are thrilled to address our peers at this immunotherapy conference,” INmune CEO Dr. R.J. Tesi stated in the news release. “By targeting myeloid derived suppressor cells (MDSC) and activating natural killer (NK) cells, we believe we can reprogram the patient’s immune system to effectively attack and defeat, or control cancer.”

To view the full press release, visit http://nnw.fm/oxW0V

About INmune Bio, Inc.

INmune Bio, Inc. is a publicly traded clinical-stage biotechnology company developing therapies targeting the innate immune system to fight disease. INmune Bio is developing three product platforms: two products that reengineer the patient’s innate immune system’s response to cancer and one product to treat neuroinflammation that is currently focused on Alzheimer’s disease. INKmune is a natural killer (“NK”) cell therapeutic that primes the patient’s NK cells to attack minimal residual disease, the remaining cancer cells that are difficult to detect, which often cause relapse. INB03 inhibits myeloid derived suppressor cells (“MDSC”), which often cause resistance to immunotherapy, such as anti-PD-1 checkpoint inhibitors. XPro1595 targets neuroinflammation, which causes microglial activation and neuronal cell death. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. For more information, visit the company’s website at www.INmuneBio.com.

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)

For more information please visit https://www.networknewswire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 212.418.1217